Autoregulation Assessment During Liver Transplantation

Sponsor
Johns Hopkins University (Other)
Overall Status
Completed
CT.gov ID
NCT01425385
Collaborator
(none)
10
1
12
0.8

Study Details

Study Description

Brief Summary

Patients with liver failure undergoing liver transplantation often have clinical or sub-clinical encephalopathy that may lead to increased intracranial pressure. The latter may lead to abnormal regulation of blood flow to the brain (cerebral autoregulation) complicating patient management during and after general anesthesia. The current methods for monitoring for elevated intracranial pressure are invasive and, thus, limited to severe encephalopathy. In this study the investigators will evaluate the potential utility of monitoring cerebral blood flow (CBF) autoregulation non-invasively using near infra-red spectroscopy in patients undergoing liver transplantation.

Condition or Disease Intervention/Treatment Phase
  • Other: Near infrared spectroscopy monitoring
  • Other: Autoregulation monitoring

Detailed Description

Hepatic encephalopathy complicating chronic liver failure in patients undergoing liver transplantation increases the risk for adverse outcomes including mortality. Even mild hepatic encephalopathy may not be recognized clinically without specific testing but can be associated with impaired functional status and reduced quality of life before liver transplantation. The changes that can be seen in chronic liver failure, (cerebral edema and increased intracranial pressure) can adversely affect cerebral blood flow autoregulation that may predispose to brain injury during the multiple hemodynamic perturbations that occur during and after liver transplantation. Currently, invasive monitoring with an intracranial "bolt" is the only method to aggressively manage patients with elevated intracranial pressure from acute liver failure and hepatic encephalopathy. The placement of an intracranial pressure catheter in patient with liver failure is associated with a risk of brain hemorrhage due the presence of a coagulopathy. Further, the risk of this type of monitoring outweighs the benefits in the patients with milder or subclinical forms of hepatic encephalopathy. In this pilot study of 20 patients undergoing liver transplantation the investigators will evaluate the feasibility of non-invasive monitoring of CBF autoregulation and assess whether autoregulation is impaired in this group of patients. The investigators hypothesize that cerebral blood flow autoregulation is impaired in patients undergoing liver transplantation based on severity of liver disease. In this situation, improved patient monitoring would allow clinicians to maintain arterial blood pressure above an individual's lower limit of cerebral blood flow autoregulation that might prevent devastating brain injury during and after surgery. Cerebral blood flow autoregulation can be continuously monitored by evaluating the correlation coefficient between cerebral blood flow velocity measured with transcranial Doppler and arterial blood pressure. The investigators have developed a novel method of autoregulation monitoring using near infrared spectroscopy that allows continuous monitoring of autoregulation with the cerebral oximetry index and the hemoglobin volume index(, a moving linear correlation coefficient between cortical tissue oxygen saturation and hemoglobin level with arterial blood pressure, respectively. The latter approach is more practical and would allow widespread autoregulation monitoring in diverse clinical settings. A secondary hypothesis of this study is that near infrared spectroscopy-based monitoring of CBF autoregulation will provide an accurate assessment of the limits of autoregulation compared with the more clinically challenging transcranial Doppler methods .

Specific Aims:
  1. To assess whether patients undergoing liver transplantation have impaired cerebral blood flow autoregulation.

  2. To evaluate whether non-invasive monitoring of cerebral blood flow autoregulation with cerebral oximetry index and hemoglobin volume index can identify the lower limit of autoregulation within 10 mmHg compared with that measured with transcranial Doppler.

Study Design

Study Type:
Observational
Actual Enrollment :
10 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Non-Invasive Assessment of Cerebral Blood Flow Autoregulation in Patients Undergoing Liver Transplantation
Study Start Date :
Sep 1, 2011
Actual Primary Completion Date :
Sep 1, 2012
Actual Study Completion Date :
Sep 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Autoregulation monitoring

Patients will be grouped into Meld Score

Other: Near infrared spectroscopy monitoring
This is an observational study without interventions
Other Names:
  • Cerebral oximetry index and hemaglobin volume index
  • Other: Autoregulation monitoring
    There are no interventions in this observational study
    Other Names:
  • Cerebral oximetry
  • Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:

      -Age > 18 years old and undergoing liver transplantation.

      Exclusion Criteria:
      • Clinical instability as judged by the attending physicians whereby autoregulation monitoring may interfere with clinical care.

      • Women of child bearing potential require a negative urine human chorionic gonadotropin (HCG) test to be enrolled.

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 The Johns Hopkins Hospital Baltimore Maryland United States 21287

      Sponsors and Collaborators

      • Johns Hopkins University

      Investigators

      • Principal Investigator: Charles W Hogue, MD, Johns Hopkins University

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Johns Hopkins University
      ClinicalTrials.gov Identifier:
      NCT01425385
      Other Study ID Numbers:
      • NA_00051645
      First Posted:
      Aug 30, 2011
      Last Update Posted:
      Aug 22, 2017
      Last Verified:
      Aug 1, 2017
      Keywords provided by Johns Hopkins University
      Additional relevant MeSH terms:

      Study Results

      No Results Posted as of Aug 22, 2017